Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2024-06-10 00:00:00 ET · period of report 2024-06-06 · accession 0001883850-24-000029 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2024-06-10 | 2024-06-06 | REGN | SCHLEIFER LEONARD S | Pres, CEO, Bd. Co-COB, Dir | S - Sale | $1,015.02 | -787 | 64.2K | -1% | -$798.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-06-06 | S | D | 787 | $1,015.02 | 64,198 | I By Trust | — | — | (F2) Represents volume-weighted average price of sales of 787 shares of Company stock on June 6, 2024 at prices ranging from $1,015.00 to $1,015.25. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 6, 2024 at each separate price. |